このページの翻訳は実験的なもので、現在開発中です。お待ちしております！

Vivesto マネジメント

マネジメント基準チェック /24

現在、CEO に関する十分な情報がありません。

主要情報

Erik Kinnman

最高経営責任者

n/a

報酬総額

CEO給与比率	n/a
CEO在任期間	1.5yrs
CEOの所有権	n/a
経営陣の平均在職期間	2.8yrs
取締役会の平均在任期間	5yrs

経営陣の近況

Recent updates

Will Vivesto (STO:VIVE) Spend Its Cash Wisely?

Apr 25

Will Vivesto (STO:VIVE) Spend Its Cash Wisely?

Aug 21

CEO（最高経営責任者

Erik Kinnman (66 yo)

1.5yrs

在職期間

cMr. Erik Kinnman, M.D., Ph D., M.B.A., Assoc. Prof., serves as Chief Executive Officer at Vivesto AB since January 23, 2023.He had been Chief Executive Officer at Sprint Bioscience AB (publ) since March...

リーダーシップ・チーム

名称	ポジション	在職期間	報酬	所有権
Erik Kinnman	Chief Executive Officer	1.5yrs	データなし	データなし
Robert Maiorana	Head of Accounting & Acting CFO	2yrs	データなし	0.0037% SEK 5.7k
Urban Ekelund	IR Manager	no data	データなし	データなし
John Cosby	Head of Regulatory Affairs	18.5yrs	データなし	データなし
Dzianis Babrou	Head of Product Development	no data	データなし	データなし
Henrik Rönnberg	Chief Medical Officer of Animal Health	8.9yrs	データなし	データなし
Maria Hagberg	Head of Regulatory Affairs	5.3yrs	データなし	データなし
Heidi Ramstad	Chief Medical Officer	1.5yrs	データなし	データなし
Johanna Rostin	Chief Regulatory Officer	2.8yrs	データなし	データなし
Kia Bengtsson	Head of Clinical Development	2.8yrs	データなし	データなし
Teresa Zafra	Head of Preclinical Development & Clinical Operations	less than a year	データなし	データなし

2.8yrs

平均在職期間

57yo

平均年齢

経験豊富な経営陣: VIVEの経営陣は経験豊富であると考えられます ( 2.7年の平均在職年数)。

取締役

名称	ポジション	在職期間	報酬	所有権
Göran Pettersson	Chairman of Business Advisory Board	5yrs	データなし	データなし
Hans Grönlund	Member of Scientific Advisory Board	5yrs	データなし	データなし
Mohammed Homman	Member of Business Advisory Board	5yrs	データなし	データなし
Jacob Kaluski	Member of Business Advisory Board	5yrs	データなし	データなし
Rolf Lewensohn	Chairman of Scientific Advisory Board	5yrs	データなし	データなし
Kerstin Strinnholm	Member of Business Advisory Board	5.1yrs	データなし	データなし
Pal Ryfors	Independent Director	2.2yrs	SEK 257.00k	データなし
Hege Hellstrom	Member of Business Advisory Board & Independent Director	5yrs	SEK 361.00k	データなし
Roger Tell	Independent Director	2.2yrs	SEK 218.00k	データなし
Ola Winqvist	Member of Scientific Advisory Board	5yrs	データなし	データなし
Peter Zonabend	Chairman of the Board	5.3yrs	SEK 612.00k	0.13% SEK 205.6k

5.0yrs

平均在職期間

59yo

平均年齢

経験豊富なボード: VIVEの取締役会は経験豊富であると考えられます ( 4.9年の平均在任期間)。

Vivesto マネジメント

マネジメント 基準チェック /24

主要情報

経営陣の近況

Vivesto AB (publ) Announces Composition of Nomination Committee

Vivesto AB Announces Appoints Erik Kinnman as CEO, Effective from January 23, 2023

Vivesto AB Announces Chief Executive Officer Changes, Effective No Later Than May 20, 2023

Vivesto AB Appoints Erik Kinnman as CEO

Vivesto AB Appoints Nomination Committee for 2023

Vivesto AB, Annual General Meeting, May 25, 2023

Recent updates

Vivesto's International Patent Application for XR-18 Receives Positive Decision

Vivesto AB's US Clinical Paccal Vet Trial Receives Approval to Start Patient Recruitment

Vivesto AB (publ) Announces Composition of Nomination Committee

Vivesto AB to Report Nine Months, 2024 Results on Nov 21, 2024

New major risk - Revenue and earnings growth

New major risk - Financial position

Vivesto AB Announces Early Termination of Patient Enrollment in the Investigator-Initiated Phase 1B Docetaxel Micellar Study

Will Vivesto (STO:VIVE) Spend Its Cash Wisely?

Full year 2022 earnings released: kr0.34 loss per share (vs kr0.30 loss in FY 2021)

Vivesto AB Announces Appoints Erik Kinnman as CEO, Effective from January 23, 2023

Vivesto AB Announces Chief Executive Officer Changes, Effective No Later Than May 20, 2023

Vivesto AB Appoints Erik Kinnman as CEO

Vivesto AB Appoints Nomination Committee for 2023

Third quarter 2022 earnings released: kr0.14 loss per share (vs kr0.069 loss in 3Q 2021)

Vivesto AB, Annual General Meeting, May 25, 2023

Price target decreased to kr1.05

Vivesto AB Announces Resignation of Christer Nordstedt as Acting Ceo, Effective 30 November 2022

Second quarter 2022 earnings released

Will Vivesto (STO:VIVE) Spend Its Cash Wisely?

Vivesto AB Appoints Christer Nordstedt as Acting CEO

Vivesto AB Announces Chief Financial Officer Changes

Vivesto AB Announces CEO Francois Martelet Agrees on Ending the Employment Relationship, Effective July 21, 2022

First quarter 2022 earnings: EPS and revenues exceed analyst expectations

Vivesto AB Announces Executive Changes

High number of new and inexperienced directors

Vivesto AB Appoints Daniel Tesfa as Chief Medical Officer

Oasmia Pharmaceutical AB announces step down of Fredrik Jarrsten as CFO

Full year 2021 earnings: Revenues exceed analysts expectations while EPS lags behind

Oasmia Pharmaceutical AB (Publ) Announces Update on Progress of Sakk Investigator-Initiated Phase 1B Trial of Docetaxel Micellar in Advanced Prostate Cancer

Oasmia Pharmaceutical Announces Progress on the Development of Its Next Generation XR-18 Drug Delivery Technology

Consensus forecasts updated

Independent Chairman recently bought kr53k worth of stock

Kazia Licenses Cantrixil, to Oasmia Pharmacetical AB

Fredrik JÃ¤rrsten to Join Oasmia Pharmaceutical AB (Publ) as CFO

Oasmia Pharmaceutical Appoints Dr. Heidi B. Ramstad as Chief Medical Officer

Oasmia Pharmaceutical AB (publ) Announces Proposed Class Action Settlement

Oasmia Pharmaceutical AB (publ) to Report Fiscal Year 2021 Results on Feb 24, 2022

Oasmia Pharmaceutical AB (publ) to Report Q3, 2021 Results on Nov 18, 2021

Oasmia Pharmaceutical AB (Publ) Announces Board Appointments

CEO（最高経営責任者

在職期間

リーダーシップ・チーム

平均在職期間

平均年齢

取締役

平均在職期間

平均年齢

マネジメント基準チェック /24